77 results about "Sevelamer" patented technology

The invention relates to sevelamer carbonate effervescent tablets and a preparation process thereof. Each sevelamer carbonate effervescent tablet is characterized by comprising the following materials in weight percentage: 30-70% of sevelamer carbonate, 10-55% of effervescing agent, 10-40% of filling agent, 1.0-10% of adhesive, 0.1-5.0% of suspending agent, 0.5-5.0% of lubricating agent and 0.05-1.0% of corrigent. The sevelamer carbonate effervescent tablets are convenient for patients to carry and capable of overcoming patients' swallowing difficulty and has better taste, so that the patients' medication compliance can be improved. Compared with the original triturate, i.e., sevelamer carbonate tablets and dry suspension (product name: RENVELA), the sevelamer carbonate effervescent tablets have short disintegration and dispersing time in water and good dispersing effect and are easy to precipitate; and the acceleration test shows that the sevelamer carbonate effervescent tablets have good stability.

A method for treating hyperglycemia and / or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

The invention belongs to the field of pharmacy, and relates to a sevelamer carbonate crude drug for preparing tablets, a preparation method and application of the sevelamer carbonate crude drug. The particle size of the sevelamer carbonate crude drug meets the conditions: D 0.95 is less than or equal to 180mu m, D 0.50 is less than or equal to 50mu m, and D 0.05 is more than or equal to 9mu m at the same time. The polyallylamine carbonate has the soluble oligomer (0.2%) within the particle size range. The tablets prepared from the sevelamer carbonate crude drug have the advantages of being smooth in surfaces, good in hardness and low in friability.

The present invention relates to a process for the preparation of cross-linked polyallylamine or a pharmaceutically acceptable salt thereof. The present invention also relates to preparation of sevelamer or a pharmaceutically acceptable salt thereof which is used in the treatment of hyperphosphatemia and has good fluidity, low porosity and / or a swelling index of 7 to 9 method, the pharmaceutically acceptable salt is preferably hydrochloride or carbonate.